Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study
Tislelizumab联合贝伐珠单抗和XELOX方案作为MSS/pMMR RAS突变型转移性结直肠癌的一线治疗(TACTIC CRC-02):一项II期研究
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.106056
Liu, X; Ou, K; Ma, X; Yang, W; Cao, B; Lu, J; Zhang, L; Gao, L; Wang, Q; Zhang, W; Jiang, Z; Zhou, A; Zhang, H; Yang, L
肿瘤
肠癌
肿瘤免疫
多发性骨髓瘤
多发性硬化症
RAS
LOX